Thermo Fisher Scientific Aktie 977576 / US8835561023
534.44
USD
4.51
USD
0.85%
03.12.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Thermo Fisher Scientific Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Thermo Fisher Scientific Inc | 0.26 | 1.40 | USD |
| 2022 | Thermo Fisher Scientific Inc | 0.22 | 1.20 | USD |
| 2021 | Thermo Fisher Scientific Inc | 0.16 | 1.04 | USD |
| 2020 | Thermo Fisher Scientific Inc | 0.19 | 0.88 | USD |
| 2019 | Thermo Fisher Scientific Inc | 0.23 | 0.76 | USD |
| 2018 | Thermo Fisher Scientific Inc | 0.30 | 0.68 | USD |
| 2017 | Thermo Fisher Scientific Inc | 0.32 | 0.60 | USD |
| 2016 | Thermo Fisher Scientific Inc | 0.43 | 0.60 | USD |
| 2015 | Thermo Fisher Scientific Inc | 0.42 | 0.60 | USD |
| 2014 | Thermo Fisher Scientific Inc | 0.48 | 0.60 | USD |
Gewinn je Aktie- Thermo Fisher Scientific
| 15.4 23 | 17.6 22 | 19.5 21 | 16.0 20 | 9.2 19 | 7.2 18 | 5.6 17 |
Umsatz je Aktie- Thermo Fisher Scientific
| 110 23 | 114 22 | 98.8 21 | 80.7 20 | 63.4 19 | 60.0 18 | 52.6 17 |
KGV- Thermo Fisher Scientific
| 34.4 23 | 31.2 22 | 34.3 21 | 29.2 20 | 35.4 19 | 30.9 18 | 34.0 17 |
Thermo Fisher Scientific Inc: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 15.45 | 17.63 | 19.46 | 15.96 | 9.17 | 7.24 | 5.59 |
| Gewinn je Aktie unverwässert | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.63 |
| Gewinn je Aktie verwässert | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 |
| Dividende pro Aktie | 1.40 | 1.20 | 1.04 | 0.88 | 0.76 | 0.68 | 0.60 |
| Gesamtdividendenausschüttung in Mio. | 523.00 | 455.00 | 395.00 | 337.00 | 297.00 | 266.00 | 237.00 |
Thermo Fisher Scientific Inc: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 110.46 | 114.00 | 98.77 | 80.75 | 63.38 | 60.00 | 52.56 |
| KGV (Jahresendkurs, EPS unverwässert) | 34.35 | 31.22 | 34.29 | 29.15 | 35.42 | 30.91 | 33.97 |
| KGV (Jahresendkurs, EPS verwässert) | 34.35 | 31.22 | 34.29 | 29.15 | 35.42 | 30.91 | 33.97 |
| KGV (Jahresendkurs) | 34.35 | 31.22 | 34.29 | 29.15 | 35.42 | 30.91 | 33.97 |
| Dividendenrendite Jahresende in % | 0.26 | 0.22 | 0.16 | 0.19 | 0.23 | 0.30 | 0.32 |
| Eigenkapitalquote in % | 47.45 | 45.44 | 43.08 | 49.97 | 50.83 | 49.06 | 44.84 |
| Fremdkapitalquote in % | 52.55 | 54.56 | 56.92 | 50.03 | 49.17 | 50.94 | 55.16 |
Thermo Fisher Scientific Inc: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 42’857.00 | 44’915.00 | 39’211.00 | 32’218.00 | 25’542.00 | 24’358.00 | 20’918.00 |
| Umsatzveränderung in % | -4.58 | 14.55 | 21.71 | 26.14 | 4.86 | 16.45 | 14.47 |
| Bruttoergebnis vom Umsatz | 17’194.00 | 19’011.00 | 19’634.00 | 16’027.00 | 11’344.00 | 10’988.00 | 9’679.00 |
| Bruttoergebnisveränderung in % | -9.56 | -3.17 | 22.51 | 41.28 | 3.24 | 13.52 | 12.78 |
| Operatives Ergebnis | 7’446.00 | 8’525.00 | 10’318.00 | 7’926.00 | 4’259.00 | 3’872.00 | 3’267.00 |
| Veränderung Operatives Ergebnis in % | -12.66 | -17.38 | 30.18 | 86.10 | 9.99 | 18.52 | 14.27 |
| Ergebnis vor Steuern | 6’298.00 | 7’835.00 | 8’841.00 | 7’225.00 | 4’070.00 | 3’262.00 | 2’429.00 |
| Veränderung Ergebnis vor Steuern in % | -19.62 | -11.38 | 22.37 | 77.52 | 24.77 | 34.29 | 20.02 |
| Ergebnis nach Steuer | 5’995.00 | 6’950.00 | 7’725.00 | 6’375.00 | 3’696.00 | 2’938.00 | 2’228.00 |
| Veränderung Ergebnis nach Steuer in % | -13.74 | -10.03 | 21.18 | 72.48 | 25.80 | 31.87 | 10.01 |
Thermo Fisher Scientific Inc: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 51’884 | 53’006 | 54’146 | 34’545 | 28’706 | 28’646 | 31’256 |
| Langzeit Gesamtverbindlichk. pro Aktie | 97.95 | 92.18 | 103.21 | 61.11 | 56.45 | 55.95 | 60.32 |
| Eigenkapital | 46’842 | 44’148 | 40’977 | 34’507 | 29’675 | 27’586 | 25’413 |
| Veränderung Eigenkapital in % | 6.27 | 7.81 | 18.22 | 16.28 | 7.57 | 8.55 | 17.98 |
| Bilanzsumme | 98’726 | 97’154 | 95’123 | 69’052 | 58’381 | 56’232 | 56’669 |
| Veränderung Bilanzsumme in % | 1.62 | 2.14 | 37.76 | 18.28 | 3.82 | -0.77 | 23.44 |
Thermo Fisher Scientific Inc: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.63 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -12.40 | -9.57 | 21.79 | 74.23 | 26.40 | 29.77 | 10.02 |
| Gewinn je Aktie (verwässert) | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 |
| Veränderung Gewinn je Aktie (verwässert) in % | -12.41 | -9.35 | 21.79 | 74.21 | 26.67 | 29.52 | 9.82 |
| Anzahl Mitarbeiter | 122’000 | 130’000 | 130’000 | 80’000 | 75’000 | 70’000 | 70’000 |
| Veränderung Anzahl Mitarbeiter in % | -6.15 | 0.00 | 62.50 | 6.67 | 7.14 | 0.00 | 27.27 |
Thermo Fisher Scientific Inc Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Thermo Fisher Scientific Inc | Quartalszahlen | 29.01.2025 |
| Thermo Fisher Scientific Inc | Quartalszahlen | 23.04.2025 |
| Thermo Fisher Scientific Inc | Quartalszahlen | 23.07.2025 |
| Thermo Fisher Scientific Inc | Quartalszahlen | 22.10.2025 |
Thermo Fisher Scientific Inc vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 23.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 24.07.2024 |
| Hauptversammlung | Annual General Meeting | 22.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 24.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 31.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 25.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 26.07.2023 |
| Hauptversammlung | Annual General Meeting | 24.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 26.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 01.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 26.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 28.07.2022 |
| Hauptversammlung | Annual General Meeting | 18.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 02.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.86 |
| The Vanguard Group, Inc. | 8.63 |
| Vanguard Group, Inc. (Subfiler) | 8.21 |
| State Street Corp. | 4.27 |
| Vanguard Total Stock Market ETF | 3.16 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2.72 |
| Vanguard 500 Index Fund | 2.65 |
| Capital Research & Management Co. (World Investors) | 2.44 |
| BlackRock Fund Advisors | 2.29 |
| BlackRock Institutional Trust Co. NA | 2.19 |
| Capital Research & Management Co. (Global Investors) | 2.14 |
| Geode Capital Management LLC | 2.01 |
| Fidelity Management & Research Co. LLC | 1.54 |
| Norges Bank (13F) | 1.46 |
| Government Pension Fund - Global (The) | 1.43 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 70’000 | 70’000 | 75’000 | 80’000 | 130’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.30 | 0.35 | 0.34 | 0.40 | 0.30 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 9’421 | 10’625 | 11’893 | 21’957 | 20’113 |
| Summe Anlagevermögen | 47’248 | 45’607 | 46’488 | 47’095 | 75’010 |
| Summe Aktiva | 56’669 | 56’232 | 58’381 | 69’052 | 95’123 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 31’256 | 28’646 | 28’706 | 34’545 | 54’146 |
| Summe Eigenkapital | 25’413 | 27’586 | 29’675 | 34’507 | 40’977 |
| Summe Passiva | 56’669 | 56’232 | 58’381 | 69’052 | 95’123 |
Adresse
| 168 Third Avenue, 02451 Waltham | |
| Telefon | +1 (781) 622-1000 |
| Fax | +1 (781) 622-1207 |
| URL | http://www.thermofisher.com |
Management
|
Aditya Joshi
Chief Strategy Officer & Vice President |
|
Alan B. Sachs
Chief Medical Officer |
|
Anthony Hugh Smith
Treasurer, Vice President-Tax & Treasury |
|
C. Martin Harris
Independent Director |
|
Chetan Khanna
Director-Human Resources |
|
Cory Stevenson
President-Bioproduction Division |
|
Daniel P. Shine
Senior VP, President-Analytical Instruments |
|
Daniella Cramp
Senior VP & President-BioProduction Group |
|
Debora L. Spar
Independent Director |
|
Dion J. Weisler
Independent Director |
|
Frederick M. Lowery
President-Laboratory Products & Bioproduction |
|
Garret Hampton
President-Clinical Sequencing & Oncology |
|
Gianluca Pettiti
Executive Vice President |
|
James C. Mullen
Independent Director |
|
Jennifer M. Johnson
Independent Director |
|
John Brian Sabo
VP & General Counsel-Customer Channels Group |
|
Joseph Holmes
Chief Accounting Officer & Vice President |
|
Julia L. Chen
Secretary & Vice President |
|
Karen E. Nelson
Chief Scientific Officer |
|
Kathryn Miles
Vice President-Strategic Accounts |
|
Kimberlee S. Caple
Vice President & GM-Genetic Science Business |
|
Lisa P. Britt
Chief Human Resources Officer & Senior VP |
|
Marc N. Casper
Chairman, President & Chief Executive Officer |
|
Michael A. Boxer
Senior Vice President & General Counsel |
|
Michael J. Dubose
President-Fisher Healthcare Division |
|
Michel Lagarde
Chief Operating Officer & Executive Vice President |
|
Mike Shafer
Senior VP & President-Pharma Services Group |
|
Nelson J. Chai
Independent Director |
|
Paul G. Parker
Senior VP-Strategy & Corporate Development |
|
R. Alexandra Keith
Independent Director |
|
Rafael Tejada
Vice President-Investor Relations |
|
Ruby R. Chandy
Independent Director |
|
Ryan Snyder
Chief Information Officer & Senior Vice President |
|
Scott M. Sperling
Lead Independent Director |
|
Sebastian Pacios
Senior Vice President-Clinical Research |
|
Stephen Williamson
Chief Financial Officer & Senior Vice President |
|
Tyler E. Jacks
Director |